Skip to search formSkip to main contentSkip to account menu

Anistreplase

Known as: t-plasminogen activator, tPA, t- PA 
An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an… 
National Institutes of Health

Related topics

Related topics

28 relations

Narrower (3)

BRL-26921EminaseIminase
Brain NeoplasmsCerebral InfarctionCerebrovascular TraumaCongenital arteriovenous malformation

Broader (1)

Fibrinolytic Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1997
Review
1997
TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis.
Review
1995
Review
1995
Fibrinolytic Agents: Mechanisms of Activity and Pharmacology
Fibrinolytic (thrombolytic) agents activate the fibrinolytic system by conversion of the inactive proenzyme, plasminogen into the… 
1995
1995
Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction.
We report the detection of activated GP IIb-IIIa complexes on platelets of patients undergoing thrombolytic therapy after acute… 
1995
1995
The European Myocardial Infarction Project: an assessment of pre-hospital thrombolysis.
1990
1990
Reduction in hospital time to thrombolytic therapy by audit of policy guidelines.
Despite the importance of early thrombolysis in the treatment of acute myocardial infarction, unacceptable delays in drug… 
1988
1988
Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC…
Highly Cited
1987
Highly Cited
1987
Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: a placebo-controlled arteriographic coronary recanalization study.
Review
1987
Review
1987
Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.
APSAC is a new thrombolytic agent with advantages over conventional therapy such as streptokinase. In particular, it is suitable… 
Highly Cited
1986
Highly Cited
1986
Clinical effects and kinetic properties of intravenous APSAC--anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction.
Highly Cited
1986
Highly Cited
1986
Coronary thrombolysis during acute myocardial infarction by intravenous BRL 26921, a new anisoylated plasminogen-streptokinase activator complex.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)